Cargando…
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
BACKGROUND: Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explor...
Autores principales: | Munseri, Patricia. J., Kroidl, Arne, Nilsson, Charlotta, Joachim, Agricola, Geldmacher, Christof, Mann, Philipp, Moshiro, Candida, Aboud, Said, Lyamuya, Eligius, Maboko, Leonard, Missanga, Marco, Kaluwa, Bahati, Mfinanga, Sayoki, Podola, Lilly, Bauer, Asli, Godoy-Ramirez, Karina, Marovich, Mary, Moss, Bernard, Hoelscher, Michael, Gotch, Frances, Stöhr, Wolfgang, Stout, Richard, McCormack, Sheena, Wahren, Britta, Mhalu, Fred, Robb, Merlin L., Biberfeld, Gunnel, Sandström, Eric, Bakari, Muhammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398367/ https://www.ncbi.nlm.nih.gov/pubmed/25875843 http://dx.doi.org/10.1371/journal.pone.0119629 |
Ejemplares similares
-
Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
por: Munseri, P, et al.
Publicado: (2012) -
Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
por: Bauer, A, et al.
Publicado: (2012) -
Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
por: Podola, L, et al.
Publicado: (2012) -
High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania
por: Mann, PJ, et al.
Publicado: (2012) -
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
por: Joachim, Agricola, et al.
Publicado: (2016)